Journal
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
Volume 108, Issue -, Pages 13-22Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ejps.2016.08.055
Keywords
P-glycoprotein; 1,2-Dioctanoyl-sn-glycero-3-phosphocholine (8: 0 PC); 1,2-Didecanoyl-sn-glycero-3-phosphocholine (10: 0 PC); Surfactants; Ritonavir; Caco-2; Oral drug delivery
Categories
Funding
- Phospholipid e.V. (Heidelberg, Germany)
Ask authors/readers for more resources
The efflux transporter P-glycoprotein (P-gp) significantly modulates drug transport across the intestinal mucosa, strongly reducing the systemic absorption of various active pharmaceutical ingredients. P-gp inhibitors could serve as helpful tools to enhance the oral bioavailability of those substances. As a membrane-associated protein P-gp is surrounded and influenced by phospholipids. Some synthetic phospholipids have been found to strongly reduce P-gp's activity. In this study two representative phospholipids, 1,2-dioctanoyl-sn-glycero-3-phosphocholine (8: 0 PC) and 1,2-didecanoyl-sn-glycero-3-phosphocholine (10: 0 PC), were compared with Tween (R) 80 and Cremophor (R) EL, both commonly used surfactants with P-gp inhibitory properties. Their influence on the cellular transport of the P-gp substrate rhodamine 123 (RH123) was examined using Caco-2 cell layers. In addition, fluorescence anisotropy measurements were performed in order to investigate their effect on membrane fluidity. Finally, we compared the phospholipids with Tween (R) 80 and the competitive P-gp inhibitor verapamil in an in vivo study, testing their effects on the oral bioavailability of the P-gp substrate drug ritonavir. Both phospholipids not only led to the strongest absorption of RH123, but a permeability enhancing effect was detected in addition to the P-gp inhibition. Their effects on membrane fluidity were not consistent with their P-gp inhibiting effects, and therefore suggested a more complex mode of action. Both phospholipids significantly increased the area under the ritonavir plasma level curve (AUC) within 150 min by more than tenfold, but were inferior to Tween (R) 80, which showed superior solubilizing effects. Finally, these phospholipids represent a novel substance class showing a high permeabilization potential for P-gp substrates. Because of their physiological structure and intestinal degradability, good tolerability without systemic absorption is expected. Formulating P-gp substrates with an originally low oral bioavailability is a difficult task, requiring concerted interplay of all excipients. P-gp inhibiting phospholipids offer a new tool to help cope with these challenges. (C) 2016 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available